Inhibrx (NASDAQ:INBX – Get Free Report) is expected to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($2.88) per share for the quarter.
Inhibrx Stock Performance
Shares of NASDAQ INBX opened at $12.35 on Wednesday. Inhibrx has a twelve month low of $10.80 and a twelve month high of $18.95. The company has a 50 day moving average of $13.73 and a 200 day moving average of $14.60.
Analyst Upgrades and Downgrades
Separately, JMP Securities reiterated a “market perform” rating on shares of Inhibrx in a research note on Wednesday, January 22nd.
Inhibrx Company Profile
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Stories
- Five stocks we like better than Inhibrx
- What Are the U.K. Market Holidays? How to Invest and Trade
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- What is diluted earnings per share (Diluted EPS)?
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- Why Are Stock Sectors Important to Successful Investing?
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
